Valued at USD 4.26 billion in 2025, the DNA synthesis market is projected to reach USD 4.96 billion in 2026 and USD 17.24 billion by 2034, growing at a CAGR of 16.85% during the forecast period 2026–2034. Major players include Twist Bioscience Corporation, DNA Script SAS, Molecular Assemblies, Inc., Integrated DNA Technologies, Inc., GenScript Biotech Corporation, Thermo Fisher Scientific, Inc., Eurofins Scientific SE, LGC Biosearch Technologies Limited, BIONEER CORPORATION, Camena Bioscience Ltd., Eton Bioscience, Inc., IBA Lifesciences GmbH, Quintara Biosciences, Inc., Synbio Technologies, Inc., and Touchlight Genetics Ltd.

Chemical Synthesis Remains the Commercial Backbone

Chemical DNA synthesis is highly established, with broad commercial adoption across research and diagnostics. It relies on phosphoramidite chemistry to assemble DNA strands nucleotide by nucleotide, and mature manufacturing infrastructure supports cost-effective production of standard oligonucleotides. Typical applications include PCR primers, probes, gene fragments, diagnostics, and research reagents. The limitations are well understood: accuracy decreases as sequence length increases, often requiring additional error correction, and the process generates significant chemical waste while relying on hazardous solvents and reagents. These constraints are why the DNA synthesis market is closely watching alternative platforms.

Cost, Error Rates and Scalability Remain Key Challenges

Synthesizing long and complex sequences remains costly because additional synthesis and validation steps are often required. Errors can occur, especially as sequence length increases, creating challenges for downstream applications. Regulatory complexity also matters, as products used in healthcare and biotechnology must comply with different requirements across regions. Scaling production while maintaining quality, accuracy, and consistency, and the need for specialized equipment and expertise, add operational complexity for manufacturers and research organizations.

AI-Driven Automation Improves Workflow Performance

Integration of automation and AI is a major opportunity. AI-driven automation can optimize synthesis based on analysis of protocols, sequence complexity, and reagent interactions, and enables adaptive synthesis through real-time adjustment of temperature, timing, and reagent flow. AI analysis also identifies synthesis failures, reagent degradation, and contamination, minimizing waste, while assisting automated sequence design to accelerate R&D and throughput. In October 2024, the CODA platform designed synthetic DNA components with high accuracy, demonstrating the role of AI in research, therapeutics, and synthetic biology.

Read More @ https://www.polarismarketresearch.com/industry-analysis/dna-synthesis-market

Biopharma Expansion and mRNA Vaccine Development

Growth in the biopharmaceutical industry is accelerating demand for synthetic DNA used in gene constructs, antibody libraries, and synthetic vaccines. India's biopharma industry expanded from USD 10 billion in 2014 to USD 165.7 billion in 2024 and is likely to exceed USD 300 billion by 2030. Pharmaceutical and biotechnology firms held a 56.2% end-user share in 2025.

mRNA vaccine development depends on the rapid creation of DNA templates used to produce mRNA candidates, allowing researchers to design and test vaccine sequences against emerging infectious diseases. Growing investment in infectious disease research and pandemic preparedness is increasing the use of synthetic DNA, and the technology also supports faster development of diagnostic tools and genetic research programs during outbreaks.

Partnerships and Regional Leadership

Collaboration is shaping capability. In June 2026, IDT launched end-to-end oncology research workflows integrated with Illumina software, supporting targeted cancer research. In March 2025, IDT partnered with Elegen to offer early access to the ENFINIA Plasmid DNA service for complex genes of 5–15 kb.

North America led with a 42.4% share in 2025, while Europe held a substantial share, supported by Horizon Europe and high CRISPR adoption. Asia Pacific is expected to grow at a CAGR of 17.6%, powered by investment in genomics, molecular diagnostics, and vaccines. For suppliers and CDMOs, the sustained expansion of the DNA synthesis market favors those that combine technical accuracy with scalable, automated delivery. Advances in enzymatic synthesis, automation, and quality control are improving speed, reliability, and scalability, underpinning innovation across genomics, drug discovery, and bioengineering.

More Trending Latest Reports By Polaris Market Research:

ai-inference-market

all-terrain-vehicle-atv-and-utility-task-vehicle-utv-market

https://www.polarismarketresearch.com/publish-report-list

veterinary-medicine-market

smoothies-market

power-transformer-market

ready-meals-market

regtech-market

how-hospitals-are-using-predictive-analytics-to-cut-readmission-rates-and-reduce-costs